Investment Rating - The investment rating for the company is "Accumulate" (maintained) [4] Core Views - The company's performance forecast for 2025 aligns with expectations, with proprietary brand revenue expected to achieve high growth [4] - Significant growth in net profit is anticipated due to rapid revenue growth from proprietary brands, strong performance in brand management, and effective cost reduction strategies [6] - The company has established a competitive advantage in various categories, including health products, maternal and infant care, beauty and personal care, and food and beverages, which may further enhance growth potential [6] Financial Summary - Revenue projections for the company are as follows: - 2023: 1,366 million RMB - 2024: 1,766 million RMB (growth of 29.26%) - 2025: 2,934 million RMB (growth of 66.14%) - 2026: 4,374 million RMB (growth of 49.11%) - 2027: 5,401 million RMB (growth of 23.47%) [5] - Net profit forecasts are as follows: - 2023: 54 million RMB - 2024: 106 million RMB (growth of 94.58%) - 2025: 190 million RMB (growth of 79.67%) - 2026: 327 million RMB (growth of 72.07%) - 2027: 459 million RMB (growth of 40.51%) [5] - Earnings per share (EPS) projections are: - 2023: 0.17 RMB - 2024: 0.34 RMB - 2025: 0.61 RMB - 2026: 1.05 RMB - 2027: 1.48 RMB [5] Business Strategy - The company is focusing on enhancing its proprietary brand business, with successful product launches contributing to revenue growth [6] - The brand management business is also expected to see significant performance improvements through deep collaborations with multiple brands [6] - The company is implementing a refined operational strategy to optimize costs across various dimensions, including supply chain management and marketing [6]

执业证书编号：S0740519050002 城商行Ⅱ 详解青岛银行 2025 业绩快报： 资产质量改善显著，业绩维持高增 Email：dengmj@zts.com.cn 执业证书编号：S0740524090004 Email：yangcl@zts.com.cn | 总股本(百万股) | 5,820.35 | | --- | --- | | 流通股本(百万股) | 5,404.45 | | 市价(元) | 4.63 | | 市值(百万元) | 26,948.24 | | 流通市值(百万元) | 25,022.59 | 2025-10-29 2025-08-31 3、《详解青岛银行 2024 年报：业绩 高增；资产质量优化；制造业投放显 著回升》2025-03-28 | 证券研究报告/公司点评报告 | | --- | | 2026 | | 月 29 | | 青岛银行（002948.SZ） 年 01 日 | | 评级： 增持（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 指标 | 2023A | ...

详解青岛银行 2025 业绩快报： 资产质量改善显著，业绩维持高增 城商行Ⅱ 执业证书编号：S0740519050002 Email：dengmj@zts.com.cn 执业证书编号：S0740524090004 Email：yangcl@zts.com.cn | 总股本(百万股) | 5,820.35 | | --- | --- | | 流通股本(百万股) | 5,404.45 | | 市价(元) | 4.63 | | 市值(百万元) | 26,948.24 | | 流通市值(百万元) | 25,022.59 | 2025-10-29 2025-08-31 3、《详解青岛银行 2024 年报：业绩 高增；资产质量优化；制造业投放显 著回升》2025-03-28 | 证券研究报告/公司点评报告 | | --- | | 2026 | | 月 29 | | 青岛银行（002948.SZ） 年 01 日 | | 评级： 增持（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 指标 | 2023A | ...

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]

青岛银行（002948.SZ）2025 年度业绩快报点评 业绩高增，质量优异 glmszqdatemark 资料来源：Wind，国联民生证券研究所预测；（注：股价为 2026 年 1 月 28 日收盘价） 推荐 首次评级 当前价格： 4.63 元 [Table_Author] | 分析师 王先爽 | | --- | | 执业证书： S0590525120014 | | 邮箱： wangxianshuang@glms.com.cn | | 分析师 乔丹 | | 执业证书： S0590526010003 | | 邮箱： qiaodan@glms.com.cn | 相对走势 -10% 7% 23% 40% 2025/2 2025/8 2026/1 青岛银行 沪深300 [盈利预测与财务指标 Table_Forcast] | 项目/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 13,498 | 14,573 | 16,046 | 17,636 | | 增长率（%） | 8.2 | 8.0 | 10. ...

证券研究报告·公司点评报告·工业金属 鼎胜新材（603876） 2025 年业绩预告点评：电池箔盈利水平明显 提升，Q4 业绩超预期 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 19,064 | 24,022 | 26,582 | 30,163 | 33,019 | | 同比（%） | (11.76) | 26.01 | 10.66 | 13.47 | 9.47 | | 归母净利润（百万元） | 534.83 | 301.09 | 522.25 | 904.18 | 1,102.78 | | 同比（%） | (61.29) | (43.70) | 73.45 | 73.13 | 21.96 | | EPS-最新摊薄（元/股） | 0.58 | 0.32 | 0.56 | 0.97 | 1.19 | | P/E（现价&最新摊薄） | 27.21 | 48.33 | 27.86 | 16.09 | 13.20 | ...

证券研究报告·公司点评报告·其他电源设备Ⅱ 麦格米特（002851） 2025 年业绩预告点评：加大投入 ALL IN AI， 26 年业绩有望拐点加速向上 2026 年 01 月 29 日 证券分析师 曾朵红 执业证书：S0600516080001 021-60199793 zengdh@dwzq.com.cn 证券分析师 司鑫尧 执业证书：S0600524120002 sixy@dwzq.com.cn 股价走势 -24% -7% 10% 27% 44% 61% 78% 95% 112% 129% 146% 2025/2/5 2025/6/4 2025/10/1 2026/1/28 麦格米特 沪深300 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 6,754 | 8,172 | 8,683 | 12,220 | 16,613 | | 同比（%） | 23.30 | 21.00 | 6.25 | 40.72 ...

证券研究报告·公司点评报告·工业金属 鼎胜新材（603876） 2025 年业绩预告点评：电池箔盈利水平明显 提升，Q4 业绩超预期 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 19,064 | 24,022 | 26,582 | 30,163 | 33,019 | | 同比（%） | (11.76) | 26.01 | 10.66 | 13.47 | 9.47 | | 归母净利润（百万元） | 534.83 | 301.09 | 522.25 | 904.18 | 1,102.78 | | 同比（%） | (61.29) | (43.70) | 73.45 | 73.13 | 21.96 | | EPS-最新摊薄（元/股） | 0.58 | 0.32 | 0.56 | 0.97 | 1.19 | | P/E（现价&最新摊薄） | 27.21 | 48.33 | 27.86 | 16.09 | 13.20 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to increase its investment in AI, with a potential turning point in performance anticipated in 2026 [1] - The company's revenue for 2025 is projected to be 8.68 billion yuan, with a year-on-year growth of 6.25% [1] - The net profit attributable to the parent company for 2025 is forecasted to be 133.47 million yuan, reflecting a significant decline of 69.40% year-on-year [1] - The company is positioned as the only supplier of AI server power supplies for Nvidia in mainland China, with expectations for increased orders and market share [7] Financial Projections - Total revenue projections for the company are as follows: - 2023: 6.75 billion yuan - 2024: 8.17 billion yuan - 2025: 8.68 billion yuan - 2026: 12.22 billion yuan - 2027: 16.61 billion yuan [1][8] - Net profit projections are: - 2023: 629.32 million yuan - 2024: 436.12 million yuan - 2025: 133.47 million yuan - 2026: 800.61 million yuan - 2027: 1.72 billion yuan [1][8] - The earnings per share (EPS) forecast is: - 2023: 1.14 yuan - 2024: 0.79 yuan - 2025: 0.24 yuan - 2026: 1.46 yuan - 2027: 3.12 yuan [1][8] Market Data - The closing price of the company's stock is 139.18 yuan, with a market capitalization of approximately 76.56 billion yuan [5] - The price-to-earnings (P/E) ratio is currently 121.65, projected to rise to 573.63 in 2025 before decreasing to 44.54 by 2027 [1][5]

证券研究报告 特变电工 (600089 CH) 多业务板块景气共振开启价值重估 2026 年 1 月 29 日│中国内地 首次覆盖特变电工公司并给予"买入"评级，目标价 33.31 元，对应 26 年 PE 22X。我们认为公司 26 年多业务板块步入景气上行阶段，输变电业务有 望充分受益于全球高压设备紧缺外溢实现加速出海；黄金业务量价齐升；煤 炭、多晶硅拐点齐现，我们预计公司 26-27 年具备较强的向上盈利弹性。 输变电：出海有望加速突破，国内主网周期向上 公司是国内民营主变龙头，是国内少数具备"高压电缆+附件+施工"一体 化集成服务能力的企业。海外方面，全球高压电力设备持续紧缺，AIDC 进 一步放大供需缺口，国内高压电力设备企业拥抱出海新时代。公司海外订单 高速增长，23 年、24 年、25H1 公司国际市场产品分别实现签约超 7 亿美 元、超 12 亿美元、11.20 亿美元，25H1 同比增长 65.9%；截至 25H1，公 司输变电国际成套项目在手合同金额超 50 亿美元。25 年 8 月斩获沙特约 164 亿元框架标。伴随海外高盈利市场收入占比提升与供给紧张下产品价格 有望进一步推升，公司变压 ...